Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.
Fortrea Holdings Inc. (NASDAQ: FTRE) is a global contract research organization and provider of clinical development solutions to the life sciences industry. This news page aggregates company press releases and market updates related to FTRE, giving readers a focused view of how Fortrea operates as a public company and clinical development partner.
According to its own descriptions, Fortrea partners with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies. News about the company frequently highlights its work in phase I–IV clinical trial management, clinical pharmacology and consulting services, as well as its experience across more than 20 therapeutic areas and operations in about 100 countries.
Visitors can expect news items covering a range of topics, including quarterly and year-to-date financial results, guidance updates, cost-saving initiatives, and capital structure actions such as tender offers for senior secured notes. Fortrea also issues releases on leadership and governance developments, such as board appointments and executive hires, and on strategic collaborations with other organizations involved in areas like cell and gene therapy development and delivery.
Because Fortrea is listed on The NASDAQ Stock Market LLC under the symbol FTRE, its news flow also includes announcements about participation in healthcare and investor conferences, earnings calls and webcasts. Together, these updates provide insight into how Fortrea manages its clinical development services business, interacts with the investment community and responds to developments in its operating environment.
For investors, analysts and industry observers, following FTRE news offers a way to monitor the company’s financial reporting, governance changes, collaborations and other material events that Fortrea discloses through press releases and related communications.
Fortrea (Nasdaq: FTRE), a prominent global contract research organization (CRO), announced that its Chairman and CEO, Tom Pike, along with CFO Jill McConnell, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 11:00 am ET.
The presentation will be webcast live and accessible via Fortrea's Investor Relations website. A replay will be available post-event.
Fortrea (Nasdaq: FTRE), a global contract research organization, announced the appointment of Machelle Sanders to its Board of Directors on May 16, 2024.
Ms. Sanders, who has been North Carolina's Secretary of Commerce since February 2021, brings over 30 years of experience in operational and quality assurance roles within the pharmaceutical and biotechnology sectors.
Tom Pike, Fortrea’s chairman and CEO, highlighted her life sciences background and leadership skills as valuable assets for advancing Fortrea's differentiation strategy and delivering life-changing treatments faster.
Ms. Sanders expressed her enthusiasm for joining the Board and acknowledged the critical role of CROs in bringing new treatments to market.
Fortrea (Nasdaq: FTRE) reported financial results for Q1 2024 with revenues of $662.1 million, a GAAP net loss of $81.6 million, and adjusted EBITDA of $29.5 million. The company plans to divest assets related to Endpoint Clinical and Patient Access businesses. The book-to-bill ratio was 1.11x, with a backlog of $7.4 billion. Fortrea aims to be a top choice for clinical research organizations and is focused on differentiation to drive growth.
Fortrea, a leading global contract research organization (CRO), has rescheduled the release of its first quarter 2024 financial results to May 13, 2024. This delay is due to ongoing accounting and discontinued operations matters following a recent asset divestiture agreement. The company will host a conference call on the release date to discuss the financial results and conduct a Q&A session.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Fortrea Holdings (FTRE)?
What is the market cap of Fortrea Holdings (FTRE)?
